Bio-Techne climbs on quarterly revenue beat
TECH•Bio-Techne rises after revenue beats estimates
- Shares of life sciences firm Bio-Techne
TECH.Orise 1.2% to $73 premarket. - The company's Q4 revenue of $321.2 million beats analysts' average expectation of $314.7 million, according to LSEG data.
TECHreports Q4 adjusted profit of 52 cents a share, in line with analysts' average estimate.- Bio-Techne is in the process of being acquired by Germany's Merck KGaA
MRCG.DEin a deal valued at about $11.3 billion, including debt. - Up to last close, the stock is up 22.7% year to date.
